Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on X:
“Among patients with TNBC, not all residual disease post-NACT is created equal.
In a large German pooled analysis of biomarkers centrally evaluated on RD, lower Ki67 and higher TILs led to much better long-term outcomes.”
More posts featuring Paolo Tarantino on OncoDaily.